Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Textbook negotiations through and through. IPIX has been speaking to BP for several years. Several CDAs have been signed. Imagine if Leo and Dr Menon and now Dr B have been playing the confident cool cat role. This means in every meeting with BP they have been polite and grateful for the opportunity to speak and display data. Nothing more! With that they have never changed their stance. So by years later after dataset over dataset the BP know they are extremely interested but can't give in to be the bidder and show weakness or lust for the pipeline. Meanwhile Dr B has moved in and believes by throwing together 4 mid stage trials to basically prove the moa's and efficacy he could trap these BP's by providing excellent data all around. The scramble and aggressiveness will commence after these 4 topline results. It will happen. IMO.
Right. They had to act fast. Because when you're as clean and transparent as iPIX is! One has to show desperation on all possible weakness. Twisting facts and casting doubts.
Sad. Very sad.
I KNOW!!!!! Is it not amazing? I forget about that 2 point reduction equivalence. 46% Pasi 90 is $$$$$$$$$. 80% PASI 75 would be good bye! The BIDDING War would be amazing. Leo would become the mayor of fudville.....all you fudsters would get booted., tarred and feathered.
Bidding from every Big Pharm - just think. Maybe a company just decides. Here take 32 billion for everything. Please go retire.
You know what! Screw it. Let's call for a cure like pre clinical rat models showed!!!!! Tic tic tic
Thanks! Dont forget the phase 2a psoriasis trial. Mild to moderate patients and a greater or equal to 2 point reduction on IGA. That was truly a tough set of criteria. We found that in the 200mg cohort, patients that took p with the highest score in the moderate stage. (Score of 3) had a 46% rate of scoring the 2 or greater reduction.
That is why we are all so very excited. P is now dosing at 300 and 400 where Prurisol is dose dependent!!!!! Meaning more is better!!!! And because it's an existing drug we tweaked, safety is not an issue!!!!! Most companies right now would have nerves in the phase 2b trial because of the safety UNKNOWN! I think Prurisols drug (can't think of name) was safely dosed at 800-850 mg.
This is so huge and should give everyone here great confidence. We are now dosing moderate to severe patients and at a higher dose. I can only expect we see higher than 46% PASI 75
Jmo
B-OM. Fast track designation
IPIX will soon apply for Breakthrough once topline is out
Prurisol data at 6 weeks will cook the competition. 6 weeks will be better than Otezla at 16 weeks. IMO.
3-6. Months. We will know based on OM and P. Get ready IPIX longs. I hope for ATLEAST a 5 billion MC in that time frame.
Keep stating facts. It is true, the market cap will blow up after the first deal. We have 3 weeks until Q3
P results are due in Q3
Feel bad for those that sold.
Company and Science are sound. I expect HUGE returns in the next 3-6 months. We are so close to ATLEAST 2 of the 4 mid stage trial results.
Prurisol could dominate the oral psoriasis market. That is billions to whomever invests or buys outright.
The best part. IPIX owns P outright. No license or royalties are due.
That in itself is huge
Me too. Lol. MICA on ask. Never seen that MM
Mako- again. Lol. Even dumber this time
Thanks. The GREAT NEWS! We are human, this is our world and life. We only get one. DRUGS are key to life. Take B-OM, this indication I can guarantee...if trial results are lined with first 19 patients! We get approval extremely fast. We will be standard of care and prevention within 2 years.
You keep hating LEO! Go ahead and see how far that gets you. It's gotten you here and good for you I guess. But this low and dip will not last.
THE SCIENCE IS MUCH TOO STRONG
The market is oblivious here. It will recalculate like mgmt said. And it should this year. This should be above 5 here. Without a doubt in my mind. Science proving out.
No. I meant the other. Uplist and institutional buying will be very good to IPIX. This will happen after first deal. If we do not see 40 dollars by June 14th 2019, I'd be very surprised.
That's only a 5-6 billion market cap.
I will eat crap if this company is not over 40-70 dollars in the next year or 2
Leo: "...so ultimately we're working vigilantly on maturing the negotiations to landing a partner..."
MATURING THE NEGOTIATIONS.
And based on the other statements they know the data is the major negotiation tool to mature the negotiations.
IPIX!!!!!
Safety is such a HUGE deal and that is what phase 1 is for. B UP jumped straight to 2 because of previous trials. Especially OM looking so promising.
I expect a HUGE collaboration.
Trying to wrap my head around "COLLABORATIONS" and "LICENSE" deals. So here is the most recent deal that Leo was talking about:
___________________________________
Item 1.01. Entry into a Material Definitive Agreement.
On May 26, 2017, Protagonist Therapeutics, Inc. (“Protagonist” or “the Company”) and Janssen Biotech, Inc., a Pennsylvania corporation (“Janssen”), entered into an exclusive license and collaboration agreement (the “Collaboration Agreement”) for the development, manufacture and commercialization of PTG-200 worldwide for the treatment of Crohn’s disease (“CD”) and ulcerative colitis (“UC”). PTG-200 is the Company’s oral Interleukin (“IL”)-23 receptor antagonist drug candidate currently in pre-clinical development. The effectiveness of the Collaboration Agreement is subject to the expiration or termination of all applicable waiting periods under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended.
Under the Collaboration Agreement, Protagonist would grant to Janssen an exclusive worldwide license to develop, manufacture and commercialize PTG-200 and related IL-23 receptor inhibitor compounds for all indications, including CD and UC. The Company will be responsible, at its own expense, for the conduct of the Phase 1 clinical trial for PTG-200, and Janssen will be responsible for the conduct of a Phase 2 clinical trial for PTG-200 in CD. All such clinical trials would be conducted in accordance with a mutually agreed upon clinical development plan and budget. Development costs for the Phase 2 clinical trial would be shared between the parties on an 80% Janssen and 20% Protagonist basis. Should Janssen elect to retain its license following completion of the Phase 2 clinical trial, it would be responsible for the manufacture, continued development of, seeking regulatory approval for, and commercialization of PTG-200 worldwide. The parties’ development activities under the Collaboration Agreement through the Phase 2 clinical trial will be overseen by a joint governance structure which will have equal representation by both parties.
Upon the effectiveness of the Collaboration Agreement, Janssen would pay Protagonist $50 million as an initial payment. Following the conclusion of the planned Phase 2A portion of the Phase 2 clinical trial, if Janssen elects to maintain its license rights and continue the development of PTG-200 in the Phase 2B portion of such clinical trial (the “First Opt-in”), Protagonist would receive a $125 million payment. Following the conclusion of the planned Phase 2B portion of the Phase 2 clinical trial, if Janssen elects again to maintain its license rights (the “Second Opt-in”), Protagonist would receive a $200 million payment. Protagonist is eligible to receive additional potential regulatory and sales milestone payments of up to an aggregate of $615 million and tiered royalties paid as a percentage of Janssen’s worldwide net sales at rates ranging from ten to the mid-teens, with certain customary reductions in certain circumstances. If Janssen does not make either the First Opt-in or the Second Opt-in election, the Collaboration Agreement would terminate.
Protagonist would also have an option to provide up to 30% of the required U.S. details for PTG-200 to prescribers, using its own sales force personnel, upon commercial launch in the United States. If such right is exercised, the Company’s detailing costs would be reimbursed by Janssen.
__________________________________________________
This example collaboration deal is for a drug that is PRE-CLINICAL. So if we talk about Brilacidin. Let's just use the current B-UP/UC indication. We have already moved to phase 2, I would expect the same kind of deal but with more upfront cash and possibly double digit royalties instead of this example of teens.
That is jut for B-UP/UC and possibly Crohns.
Since there is more to be done with formulation I am sure there would be stipulations there as well.
The trial results and visuals on July 10th should really spark this.
For P - I think there are several other indications that could be used as well. So I am not sure if a buyout just for Psoriasis would be the most lucrative. But an infusion of cash in the 5-10Billion area would be a life changer and company changer. FOR SURE>
BK - Can you take a minute and explain how deals work in BIO for single indications. NOW it may not happen this way, but honestly I never really thought about it for IPIX and just now am more curious.
Since we could probably go a million different ways, lets just take the B franchise for example. First, is it possible to partner will multiple BP's on a single compound, but each BP has their stake in a specific indication? Does that ever happen? IF so...is it likely?
I would think BP gets the most bang for their buck if they just outright buy the compound at an end of phase 2b trial? Or do they sign a partnership for the entire platform with millions upfront and then milestones of such where they add millions to IPIX upon each new indication moving forward? Also assigning a nice healthy royalty to IPIX.
I can see a very LONG and profitable company IPIX could become if they sub license each indication with great milestone payments because there will be so many indications coming out of Brilacidin and will take time, so the news flow and milestones will be forever lasting.
So for an example: A BP signs a 20 million upfront deal for B - ABSSSI - with milestones to approval and then a double digit royalty? And then a different BP signs for B-OM - 50 million upfront and extra if they get BREAKTHROUGH and then double digit royalties? And then B for UP - etc....
I guess Have not really payed attention to date on these deals that MGMT have been suggesting. Like the JJ deal for an IBD drug for like 900 plus million. Is that just outright? Or does that company still get Royalties ontop of the 900 million?
Sorry for the terrible question layout - just throwing darts at a wall to see if you could offer a any insight on how you may think this will go down!
TIA.
This makes me think:lets partner for each indication and build a powerhouse! The safety and efficacy is unique with what we've seen now on EVERY compound thus far. It would be catalysts for YEARS UPON YEARS with almost a guaranteed success rate based on moa and safety profiles for each drug.
Wow. It just him me how rich we can become if we. Went Regeneron style.
New Blog today:
Brilacidin for IBD—A Promising Novel, Non-Corticosteroid, Non-Biologic Drug Candidate
http://www.cellceutix.com/new-blog/2017/6/14/brilacidin-for-ibda-promising-novel-non-corticosteroid-non-biologic-drug-candidate
Prurisol for Psoriasis: The GOAL: A Best-In-Class Oral Drug...
...that treats many types of psoriasis, regardless of disease severity and with an efficacy approaching that of biologics but without the harmful side effects.
For the past several months, the B-OM trial has been recruiting 1 patient per week. Interim data had 19 that completed ATLEAST 5 weeks of dosing. That was end of march.
So there has to be ATLEAST 20-24 new patients dosing. IMO
That is a huge step fwd
I just listened to the CC for the 3rd time. Here is something that I missed. First Leo suggested that the several BP's that have CDA's are for single compounds and also multiple compounds.
Then, through out the entire conference call and questions they actually admit which compounds have had discussions and at what point.
For example: They Dr. B said they actually went to BP and had a meeting about K. They then switched the direction per BP:
1) Attempt to make K an oral drug
2) Prove the MOA. This is happening now with Dr's dissecting the tumor after the treatment and other testing.
That is very encouraging.
Dr. B also mentioned that they have a CDA just for Prurisol and these BP's have made it clear just how valuable P could be if they meet Otezla's numbers.
Lastly they mentioned several times a CDA for B, especially for UP.
I personally think that B will be the first drug partnered ,UNLESS P 6 week interim data in Q3 comes out and the numbers blow away all expectations. I also believe by early next year we see BREAKTHROUGH designation from the FDA.
Great conference call again. They are so sure of the drugs it is awesome. The fact that every trial has been extremely successful thus far just proves to all new investors, there is no reason to doubt.
It's hilarious: the FUD'sters - Bring up RS - Leo shuts that down AGAIN!
the FUD'sters cry and whine there about the CC not having live callers, lol.....you bet there were live callers and questions.
Bahahhahah!
I wish I could buy that much. Man O man!!! Running down fierce biotech news daily really gives one perspective on how awesome IPIX is doing in trials. The issues other companies have with making the medicine alone for trials is crazy. I'm happy this company is so detailed.
Way before. My 11 year old niece has better knowledge of biotech value.
Prurisol is well worth over 2 billion if it comes up just short or equal to Otezla. IMO.
Do u have the audio of Dave the coo talking about the new Gen3 platform? I'm just getting back into town and catching up
I listened finally tonight. Great stuff. You just can't be more confident. IMO. It confirmed just how deep in convos with BP this company is. They know their value but are keeping all possibilities open.
I'd think we see a partner very soon for B or P
which is not on the table."
Good morning. Last day of CTIX! It's been fun but I can't wait for the future
Bahahaaaa! Bye Felicia
Maybe we also get some really good news too? How would that feel shorty?
Where's bunny? Max?
Interesting post
Fryyyyyyyy!!!! Baby FRY! All shares need to be accounted for.
I was calling this today. Wow. I should post my email to my associate. Never thought it would really happen!!!! I was just screwing around
Hoping we hit that 1.02 today. Come on afternoon buying into tomorrow's Conference Call!!!
Great point.
Yeah that was the phase 2a. Mild to moderate trial. That s done gov. We are onto moderate to severe.